Clinical Trial Update: RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 open-label study evaluating the safety and efficacy of CABA-201 in active systemic lupus erythematosus (including lupus nephritis). The trial is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• CABA-201

Snippet

Sponsor: Cabaletta Bio | Conditions: Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1, Phase 2 | Status: RECRUITING